New drug combo tested for ovarian cancer that resists standard treatment
NCT ID NCT02867956
Summary
This study tested whether adding a drug called apatinib to a standard chemotherapy (etoposide) could help control ovarian cancer that had stopped responding to platinum-based treatments. It involved 35 women with advanced ovarian cancer to see if the combination was effective and safe. The goal was to find a better option for patients whose cancer had become resistant to standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.